, Il est important de noter qu'au regard de l'origine multiple des données et de leurs sources potentielles différentes, l'effet relié à une molécule peut différer selon ses données

, A cet effet, il est également important de noter que les conclusions défendues dans ce travail ne représentent pas l'opinion des différents centres nationaux ni de l'UMC

J. M. Zito, D. J. Safer, S. Dosreis, J. F. Gardner, M. Boles et al., Trends in the prescribing of psychotropic medications to preschoolers, JAMA, vol.283, issue.8, pp.1025-1055, 2000.

H. Verdoux, M. Tournier, and B. Bégaud, Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies, Acta Psychiatr Scand, vol.121, issue.1, pp.4-10, 2010.

R. A. Sansone and L. A. Sansone, Is seroquel developing an illicit reputation for misuse/abuse? Psychiatry Edgmont Pa Townsh, vol.7, pp.13-19, 2010.

A. F. Lehman, J. A. Lieberman, L. B. Dixon, T. H. Mcglashan, A. L. Miller et al., Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry, vol.161, issue.2, pp.1-56, 2004.

, NICE MTA Guidance 43-Guidance on the use of newer (atypical) antipsychotic drugs for treatment of schizophrenia, 2018.

J. Singh, G. Chen, and C. M. Canuso, Antipsychotics in the treatment of bipolar disorder, Handb Exp Pharmacol, issue.212, pp.187-212, 2012.

R. Weisler, R. S. Mcintyre, and M. Bauer, Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy, Expert Rev Neurother, vol.13, issue.11, pp.1183-200, 2013.

N. S. Philip, K. Mello, L. L. Carpenter, A. R. Tyrka, and L. H. Price, Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use, Ann Clin Psychiatry Off J Am Acad Clin Psychiatr, vol.20, issue.1, pp.15-20, 2008.

S. G. Siris, Pharmacological treatment of substance-abusing schizophrenic patients, Schizophr Bull, vol.16, issue.1, pp.111-133, 1990.

E. Akerele and F. R. Levin, Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia, Am J Addict, vol.16, issue.4, pp.260-268, 2007.

W. Thompson, T. Quay, C. Rojas-fernandez, B. Farrell, and L. M. Bjerre, Atypical antipsychotics for insomnia: a systematic review, Sleep Med, vol.22, pp.13-20, 2016.

M. M. Koola, H. J. Wehring, and D. L. Kelly, The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use, J Dual Diagn, vol.8, issue.1, pp.50-61, 2012.

H. S. Temmingh, T. Williams, N. Siegfried, and D. J. Stein, Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database Syst Rev, vol.1, p.11057, 2018.

J. M. Pierre, I. Shnayder, D. A. Wirshing, and W. C. Wirshing, Intranasal quetiapine abuse, Am J Psychiatry, vol.161, issue.9, p.1718, 2004.

D. Murphy, K. Bailey, M. Stone, and W. C. Wirshing, Addictive potential of quetiapine, Am J Psychiatry, vol.165, issue.7, p.918, 2008.

D. L. Rowe, Off-label prescription of quetiapine in psychiatric disorders, Expert Rev Neurother, vol.7, issue.7, pp.841-52, 2007.

J. Brett, Concerns about quetiapine. Aust Prescr, vol.38, pp.95-102, 2015.

G. Tarasoff and K. Osti, Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada, Am J Psychiatry, vol.164, issue.2, p.350, 2007.

. Hussain-m-z, W. Waheed, and S. Hussain, Intravenous Quetiapine Abuse, Am J Psychiatry, vol.162, issue.9, p.1755, 2005.

A. Haridas, . Mrcpsych, D. Kushon, S. Gurmu, and O. Oluwabusi, Smoking Quetiapine: A "Maq Ball"? Prim Psychiatry, vol.17, pp.38-47, 2010.

B. M. Waters and K. G. Joshi, Intravenous quetiapine-cocaine use ('Q-ball'), Am J Psychiatry, vol.164, issue.1, pp.173-177, 2007.

R. M. Malow, J. A. West, S. A. Corrigan, J. M. Pena, and W. C. Lott, Cocaine and speedball users: differences in psychopathology, J Subst Abuse Treat, vol.9, issue.4, pp.287-91, 1992.

M. E. Mclarnon, H. G. Fulton, C. Macisaac, and S. P. Barrett, Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program, J Clin Psychopharmacol, vol.32, issue.5, pp.721-724, 2012.

H. J. Cha, H. Lee, J. Ahn, J. Kim, E. J. Jeong et al., Dependence potential of quetiapine: behavioral pharmacology in rodents, Biomol Ther, vol.21, issue.4, pp.307-319, 2013.

R. E. Brutcher, S. H. Nader, and M. A. Nader, Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys, J Pharmacol Exp Ther, vol.356, issue.2, pp.244-50, 2016.

O. V. Tcheremissine, Is quetiapine a drug of abuse? Reexamining the issue of addiction, Expert Opin Drug Saf, vol.7, issue.6, pp.739-787, 2008.

G. S. Alexopoulos, J. Streim, D. Carpenter, and J. P. Docherty, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients, J Clin Psychiatry, vol.65, issue.2, pp.5-99, 2004.

A. Sarker, K. O'connor, R. Ginn, M. Scotch, K. Smith et al., Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter, Drug Saf, vol.39, issue.3, pp.231-271, 2016.

, Lord Infamous (Ft. Lil Wyte, Partee & Project Pat)-Pill Popper, 2018.

L. Wyte-oxycotton, , 2018.

J. B. Stafford and L. Burns, Australian drug trends 2011: findings from the illicit drug reporting system (idrs), 2012.

J. Lee, J. Pilgrim, D. Gerostamoulos, J. Robinson, and A. Wong, Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia. Drug Alcohol Depend, vol.187, pp.95-104, 201801.

L. Reccoppa, Less abuse potential with XR formulation of quetiapine?, Am J Addict, vol.20, issue.2, p.178, 2011.

H. Peyrière, C. Diot, C. Eiden, and P. Petit, Réseau des Centres d'Addictovigilance

. Therapie, , 2015.

R. R. Reeves, Abuse of olanzapine by substance abusers, J Psychoactive Drugs, vol.39, issue.3, pp.297-306, 2007.

R. Dhar, A. Sidana, T. Singh, and . Olanzapine-dependence, Ger J Psychiatry, vol.13, 2010.

C. Lai, Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression, Prog Neuropsychopharmacol Biol Psychiatry, vol.34, issue.7, pp.1363-1367, 2010.

N. A. Kumsar and A. Erol, Olanzapine abuse, Subst Abus, vol.34, issue.1, pp.73-77, 2013.

D. James, P. , S. Fida, A. Konovalov, P. et al., Non-medical use of olanzapine by people on methadone treatment, vol.40, pp.314-321, 2016.

G. Valeriani, O. Corazza, F. S. Bersani, C. Melcore, A. Metastasio et al., Olanzapine as the ideal 'trip terminator'? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substancerelated psychotic symptoms, Hum Psychopharmacol, vol.30, issue.4, pp.249-54, 2015.

N. D. Volkow, Substance Use Disorders in Schizophrenia-Clinical Implications of Comorbidity, vol.35, pp.469-72, 2009.

A. A. Grace, The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving, Addict Abingdon Engl, vol.95, issue.2, pp.119-128, 2000.

R. A. Wise, Roles for nigrosriatal-not just mesocorticolimbic-dopamine in reward and addiction, Trends Neurosci, vol.32, issue.10, pp.517-541, 2009.

J. P. Bolam and T. J. Ellender, Histamine and the striatum, Neuropharmacology, vol.2016, pp.74-84

G. F. Koob, Neural Mechanisms of Drug Reinforcement, Ann N Y Acad Sci, vol.654, issue.1, pp.171-91, 1992.

W. K. Kroeze, S. J. Hufeisen, B. A. Popadak, S. M. Renock, S. Steinberg et al., H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.28, issue.3, pp.519-545, 2003.

B. A. Fischer and D. L. Boggs, The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature, Neurosci Biobehav Rev, vol.34, issue.4, pp.555-563, 2010.

, Meta regression: Relationship between antipsychotic receptor binding profiles and sideeffects, Prog Neuropsychopharmacol Biol Psychiatry, vol.84, pp.272-81, 2018.

J. A. Inciardi, H. L. Surratt, S. P. Kurtz, and T. J. Cicero, Mechanisms of prescription drug diversion among drug-involved club-and street-based populations, Pain Med Malden Mass, vol.8, issue.2, pp.171-83, 2007.

M. E. Mattson, V. A. Albright, J. Yoon, and C. L. Council, Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN), Subst Abuse Res Treat, vol.9, pp.39-46, 2015.

A. Srivastava, V. Patil, D. Silva-pereira, and Y. , A case series of quetiapine addiction/dependence, Ger J Psychiatry, vol.16, pp.152-157, 2013.

S. Chiappini and F. Schifano, Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database, J Clin Psychopharmacol, vol.38, issue.1, pp.72-81, 2018.

V. K. Patadia, P. Coloma, M. J. Schuemie, R. Herings, R. Gini et al., Using real-world healthcare data for pharmacovigilance signal detection-the experience of the EU-ADR project, Expert Rev Clin Pharmacol, vol.8, issue.1, pp.95-102, 2015.

S. Chiappini and F. Schifano, A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database, CNS Drugs, vol.30, issue.7, pp.647-54, 2016.

M. D. Cheatle, Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety, Pain Med Malden Mass, vol.16, issue.1, pp.3-8, 2015.

A. Casati, R. Sedefov, and T. Pfeiffer-gerschel, Misuse of medicines in the European Union: a systematic review of the literature, Eur Addict Res, vol.18, issue.5, pp.228-273, 2012.

C. Victorri-vigneau, E. Dailly, G. Veyrac, and P. Jolliet, Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey, Br J Clin Pharmacol, vol.64, issue.2, pp.198-209, 2007.

F. Jalali, R. Afshari, and A. Babaei, Smoking crushed hyoscine/scopolamine tablets as drug abuse. Subst Use Misuse, vol.49, pp.793-800, 2014.

D. Baribeau and K. F. Araki, Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent, J Addict Med, vol.7, issue.3, pp.216-223, 2013.

G. Francesconi, L. Orsolini, D. Papanti, J. M. Corkery, and F. Schifano, Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences, Hum Psychopharmacol, vol.30, issue.4, pp.255-61, 2015.

L. Garcin, L. Roch, M. Agbessi, C. Lobut, J. Lecoeur et al., Arch Pediatr Organe Off Soc Francaise Pediatr, vol.23, pp.1165-1173, 2016.

W. Eggleston, J. M. Marraffa, C. M. Stork, M. Mercurio-zappala, M. K. Su et al., Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse, MMWR Morb Mortal Wkly Rep, vol.65, issue.45, pp.1276-1283, 2008.

G. T. Helmerhorst, T. Teunis, S. J. Janssen, and D. Ring, An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next?, Bone Jt J, issue.7, pp.856-64, 2017.

K. B. Hoffman, A. R. Demakas, M. Dimbil, N. P. Tatonetti, and C. B. Erdman, Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS), Drug Saf, vol.37, issue.11, pp.971-80, 2014.

E. Jouanjus, V. Gibaja, J. Kahn, F. Haramburu, and A. Daveluy, Signal identification in addictovigilance: the functioning of the French system, Therapie, vol.70, issue.2, pp.113-144, 2015.

L. Klein, S. Bangh, and J. B. Cole, Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics, West J Emerg Med, vol.18, issue.2, pp.243-50, 2017.

U. Story, , 2018.

W. Index, , 2018.

. Umc-|-vigilyze, , 2018.

A. Bate, M. Lindquist, I. R. Edwards, S. Olsson, R. Orre et al., A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol, vol.54, issue.4, pp.315-336, 1998.

G. N. Norén, J. Hopstadius, and A. Bate, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery, Stat Methods Med Res, vol.22, issue.1, pp.57-69, 2013.

, Guideline On The Use Of Statistical Signal Detection Methods In The Eudravigilance Data Analysis System, 2018.

T. Renoir, Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved, Front Pharmacol, vol.4, p.45, 2013.

M. George, M. Haasz, A. Coronado, S. Salhanick, L. Korbel et al., Acute dyskinesia, myoclonus, and akathisa in an adolescent male abusing quetiapine via nasal insufflation: a case study, BMC Pediatr, vol.13, p.187, 2013.

T. Bergvall, G. N. Norén, and M. Lindquist, vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues, Drug Saf, vol.37, issue.1, pp.65-77, 2014.

L. Hazell and S. Shakir, Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-96, 2006.

B. Bégaud, K. Martin, F. Haramburu, and N. Moore, Rates of spontaneous reporting of adverse drug reactions in France, JAMA, vol.288, issue.13, p.1588, 2002.

A. Cerovecki, R. Musil, A. Klimke, F. Seemüller, E. Haen et al., Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations, CNS Drugs, vol.27, issue.7, pp.545-72, 2013.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5ème édition, 2013.

S. M. Stahl and D. K. Shayegan, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice, J Clin Psychiatry, vol.64, pp.6-12, 2003.

M. S. Gómez-criado, M. Bernardo, . Florez-t-de, J. R. Gutiérrez, R. Gandía et al., Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review, Pharmacotherapy, vol.25, issue.11, pp.1660-1665, 2005.

, , 2018.

M. Pompili, C. Verzura, G. Trovini, A. Buscajoni, G. Falcone et al., Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders, Expert Opin Drug Saf, vol.17, issue.2, pp.197-205, 2018.

G. P. Molnar, L. C. Grimsich, G. Catalano, and M. C. Catalano, Acute lurasidone overdose, J Clin Psychopharmacol, vol.34, issue.6, pp.768-70, 2014.

E. R. Pinta and R. E. Taylor, Quetiapine addiction?, Am J Psychiatry, vol.164, issue.1, pp.174-179, 2007.

G. I. Spielmans, M. I. Berman, E. Linardatos, N. Z. Rosenlicht, A. Perry et al., Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes, PLoS Med, vol.10, issue.3, p.1001403, 2013.

M. A. Ciranni, T. E. Kearney, and K. R. Olson, Comparing acute toxicity of first-and secondgeneration antipsychotic drugs: a 10-year, retrospective cohort study, J Clin Psychiatry, vol.70, issue.1, pp.122-131, 2009.

J. Faillie, Case-non case studies: Principles, methods, bias and interpretation
URL : https://hal.archives-ouvertes.fr/hal-01741153

. Therapie, , 2017.

T. Paparrigopoulos, D. Karaiskos, and J. Liappas, Quetiapine: another drug with potential for misuse? A case report, J Clin Psychiatry, vol.69, issue.1, pp.162-165, 2008.

A. K. Morin, Possible intranasal quetiapine misuse, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.64, issue.7, pp.723-728, 2007.

J. Ballon and T. S. Stroup, Polypharmacy for schizophrenia, Curr Opin Psychiatry, vol.26, issue.2, pp.208-221, 2013.

, Available from: /CD005581/SCHIZ_antidepressants-for-the-negative-symptomsof-schizophrenia, 2018.

J. Tiihonen, J. T. Suokas, J. M. Suvisaari, J. Haukka, and P. Korhonen, Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, vol.69, pp.476-83, 2012.

P. Thoma and I. Daum, Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings, Psychiatry Clin Neurosci, vol.67, issue.6, pp.367-83, 2013.

C. Yuodelis-flores and R. K. Ries, Addiction and suicide: A review, Am J Addict, vol.24, issue.2, pp.98-104, 2015.

S. Darke, Pathways to heroin dependence: time to re-appraise self-medication, Addict Abingdon Engl, vol.108, issue.4, pp.659-67, 2013.

. Umc-|-vigibase, , 2018.

M. H. Meier, A. Caspi, A. Reichenberg, R. Keefe, H. L. Fisher et al., Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study, Am J Psychiatry, vol.171, issue.1, pp.91-101, 2014.

I. X. Bibliographie, Principaux repères sur la schizophrénie [Internet]. World Health Organization, vol.1, 2018.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5ème édition, 2013.

F. López-muñoz, C. Álamo, E. Cuenca, W. Shen, P. Clervoy et al., History of the Discovery and Clinical Introduction of Chlorpromazine. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr, vol.17, pp.113-148, 2005.

M. J. Peluso, S. W. Lewis, T. Barnes, and P. B. Jones, Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs, Br J Psychiatry, issue.5, pp.387-92, 0200.

M. Raja, Clozapine safety, 35 years later, Curr Drug Saf, vol.6, issue.3, pp.164-84, 2011.
DOI : 10.2174/157488611797579230

P. Seeman, Dopamine receptors and the dopamine hypothesis of schizophrenia, Synapse, vol.1, issue.2, pp.133-52, 1987.

A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry, vol.13, issue.5, pp.318-78, 2012.

S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet Lond Engl, vol.373, issue.9657, pp.31-41, 2009.

R. A. Sansone and L. A. Sansone, Is seroquel developing an illicit reputation for misuse/abuse? Psychiatry Edgmont Pa Townsh, vol.7, pp.13-19, 2010.

J. Singh, G. Chen, and C. M. Canuso, Antipsychotics in the treatment of bipolar disorder, Handb Exp Pharmacol, issue.212, pp.187-212, 2012.

S. Suttajit, M. Srisurapanont, N. Maneeton, and B. Maneeton, Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther, vol.8, pp.827-865, 2014.

J. M. Pierre, I. Shnayder, D. A. Wirshing, and W. C. Wirshing, Intranasal quetiapine abuse, Am J Psychiatry, vol.161, issue.9, p.1718, 2004.

. Hussain-m-z, W. Waheed, and S. Hussain, Intravenous Quetiapine Abuse, Am J Psychiatry, vol.162, issue.9, p.1755, 2005.

E. R. Pinta and R. E. Taylor, Quetiapine addiction?, Am J Psychiatry, vol.164, issue.1, pp.174-179, 2007.

M. D. Cheatle, Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety, Pain Med Malden Mass, vol.16, issue.1, pp.3-8, 2015.
DOI : 10.1111/pme.12904

URL : https://academic.oup.com/painmedicine/article-pdf/16/suppl_1/S3/7497672/16-suppl_1-S3.pdf

J. Brett and B. Murnion, Management of benzodiazepine misuse and dependence. Aust Prescr, vol.38, pp.152-157, 2015.

C. Victorri-vigneau, E. Dailly, G. Veyrac, and P. Jolliet, Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey, Br J Clin Pharmacol, vol.64, issue.2, pp.198-209, 2007.

J. Lee, J. Pilgrim, D. Gerostamoulos, J. Robinson, and A. Wong, Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia. Drug Alcohol Depend, vol.187, pp.95-104, 201801.

S. Chiappini and F. Schifano, Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database, J Clin Psychopharmacol, vol.38, issue.1, pp.72-81, 2018.

G. Valeriani, O. Corazza, F. S. Bersani, C. Melcore, A. Metastasio et al., Olanzapine as the ideal 'trip terminator'? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substancerelated psychotic symptoms, Hum Psychopharmacol, vol.30, issue.4, pp.249-54, 2015.

R. R. Reeves, Abuse of olanzapine by substance abusers, J Psychoactive Drugs, vol.39, issue.3, pp.297-306, 2007.

M. Crocq, Historical and cultural aspects of man's relationship with addictive drugs, Dialogues Clin Neurosci, vol.9, pp.355-61, 2007.

, Agence technique de l'information sur l'hospitalisation. Classification statistique internationale des maladies et des problèmes de santé connexes, Sect. Bulletin officiel N° 2015/ 9bis. Fascicule spécial

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-1). 1ème édition, 1952.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-2). 2ème édition, 1968.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-3). 3ème édition, 1980.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-3-TR) Révisé. 3ème édition, 1987.

, Association Américaine de Psychiatrie. Diagnostic and Statistical Manual of Mental Disorders (DSM-4). 1ème édition, vol.176, 1994.

. Oms-|-catégories, , 2018.

, Les Conventions internationales relatives au contrôle des drogues, 2018.

, Représentation permanente de la France auprès des Organisations Internationales et des Nations unies à Vienne, Organe international de contrôle des stupéfiants (OICS), 2018.

, Code de la santé publique-Article L5311-2. Code de la santé publique

, Code de la santé publique-Article R5131-7. Code de la santé publique

L. , , 2018.

, Système d'identification des substances SINTES-OFDT, 2018.

. Emcdda-|-about, , 2018.

N. D. Volkow, J. S. Fowler, G. J. Wang, R. Baler, and F. Telang, Imaging dopamine's role in drug abuse and addiction, Neuropharmacology, vol.56, pp.3-8, 2009.

N. D. Volkow, G. J. Wang, M. W. Fischman, R. Foltin, J. S. Fowler et al., Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain, Life Sci, vol.67, issue.12, pp.1507-1522, 2000.

W. Schultz, Dopamine signals for reward value and risk: basic and recent data, vol.6, p.24, 2010.

R. A. Wise, Roles for nigrosriatal-not just mesocorticolimbic-dopamine in reward and addiction, Trends Neurosci, vol.32, issue.10, pp.517-541, 2009.

N. D. Volkow and J. S. Fowler, Addiction, a Disease of Compulsion and Drive: Involvement of the Orbitofrontal Cortex, Cereb Cortex, vol.10, issue.3, pp.318-343, 2000.

N. Volkow, Y. Ding, J. Fowler, and G. Wang, Cocaine addiction: Hypothesis derived from imaging studies with PET, vol.15, 1996.

N. D. Volkow, G. Wang, J. S. Fowler, D. Tomasi, and F. Telang, Addiction: Beyond dopamine reward circuitry, Proc Natl Acad Sci, vol.108, issue.37, pp.15037-15079, 2011.

N. D. Volkow, J. S. Fowler, and G. Wang, The addicted human brain: insights from imaging studies, J Clin Invest, vol.111, issue.10, pp.1444-51, 2003.

P. W. Kalivas, The glutamate homeostasis hypothesis of addiction, Nat Rev Neurosci, vol.10, issue.8, pp.561-72, 2009.

, Résumé Analytique, Conclusions Et Incidences Stratégique, 2018.

, Report of the International Narcotics Control Board for 2006. International Narcotics Control Board. Geneva, United Nations, 2007.

M. Kuehn and B. , Prescription Drug Abuse Rises Globally, JAMA J Am Med Assoc, vol.297, p.1306, 2007.

-. Infographies and . Ofdt, , 2018.

N. Buhrich, A. Weller, and P. Kevans, Misuse of anticholinergic drugs by people with serious mental illness, Psychiatr Serv Wash DC, vol.51, issue.7, pp.928-937, 2000.

S. Chiappini and F. Schifano, A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database, CNS Drugs, vol.30, issue.7, pp.647-54, 2016.

D. Baribeau and K. F. Araki, Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent, J Addict Med, vol.7, issue.3, pp.216-223, 2013.

G. Francesconi, L. Orsolini, D. Papanti, J. M. Corkery, and F. Schifano, Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences, Hum Psychopharmacol, vol.30, issue.4, pp.255-61, 2015.

W. Eggleston, J. M. Marraffa, C. M. Stork, M. Mercurio-zappala, M. K. Su et al., Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse, MMWR Morb Mortal Wkly Rep, vol.65, issue.45, pp.1276-1283, 2008.

G. T. Helmerhorst, T. Teunis, S. J. Janssen, and D. Ring, An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next?, Bone Jt J, issue.7, pp.856-64, 2017.

A. Moskowitz and G. Heim, Eugen Bleuler's Dementia Praecox or the Group of Schizophrenias (1911): A Centenary Appreciation and Reconsideration, Schizophr Bull, vol.37, issue.3, pp.471-480, 2011.

S. Leucht, T. Burkard, J. Henderson, M. Maj, and N. Sartorius, Physical illness and schizophrenia: a review of the literature, Acta Psychiatr Scand, vol.116, issue.5, pp.317-350, 2007.

. Schizophrénie, , 2018.

A. Millier, Humanistic burden in schizophrenia: A literature review, J Psychiatr Res, vol.54, pp.85-93, 2014.

D. Tidemalm, M. Waern, C. Stefansson, S. Elofsson, and B. Runeson, Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services, Clin Pract Epidemiol Ment Health CP EMH, vol.4, p.23, 2008.

B. A. Palmer, V. S. Pankratz, and J. M. Bostwick, The lifetime risk of suicide in schizophrenia: A reexamination. Arch Gen Psychiatry, vol.62, pp.247-53, 2005.

R. Tandon, M. S. Keshavan, A. Henry, . Nasrallah, and . Schizophrenia, Just the Facts" What we know in 2008. 2. Epidemiology and etiology-Schizophr Res, vol.106, pp.89-107, 2008.

D. C. Glahn, A. R. Laird, I. Ellison-wright, S. M. Thelen, J. L. Robinson et al., Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis, Biol Psychiatry, vol.64, issue.9, pp.774-81, 2008.

E. Bramon, C. Mcdonald, R. J. Croft, S. Landau, F. Filbey et al., Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study, NeuroImage, vol.27, issue.4, pp.960-968, 2005.

M. Laruelle, Imaging dopamine transmission in schizophrenia: A review and metaanalysis. Q J Nucl Med Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR, vol.42, pp.211-232, 1998.

S. Kapur, O. Agid, R. Mizrahi, and M. Li, How antipsychotics work-From receptors to reality, NeuroRx, vol.3, issue.1, pp.10-21, 2006.

J. Van-os and K. S. Schizophrenia, Lancet Lond Engl, vol.374, issue.9690, pp.635-680, 2009.

S. Kapur, Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia | American Journal of Psychiatry, vol.160, pp.13-23, 2003.

S. Kapur, How antipsychotics become anti-'psychotic'-from dopamine to salience to psychosis, Trends Pharmacol Sci, vol.25, issue.8, pp.402-408, 2004.

R. C. Kessler, C. B. Nelson, K. A. Mcgonagle, M. J. Edlund, R. G. Frank et al., The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization, Am J Orthopsychiatry, vol.66, issue.1, pp.17-31, 1996.

R. C. Kessler, S. Aguilar-gaxiola, L. Andrade, R. Bijl, G. Borges et al.,

. Psychiatria and . Fennica, , vol.32, pp.62-79, 2001.

C. S. Rosen, E. Kuhnmark, A. Greenbaumkent, and D. Drescher, Substance AbuseRelated Mortality Among Middle-Aged Male VA Psychiatric Patients, vol.59

, Issue 3 Psychiatric Services March, vol.59, 2008.

C. D. Swofford, J. W. Kasckow, G. Scheller-gilkey, and L. B. Inderbitzin, Substance use: a powerful predictor of relapse in schizophrenia, Schizophr Res, vol.20, issue.1, pp.145-51, 1996.

C. D. Swofford, G. Scheller-gilkey, A. H. Miller, B. Woolwine, and R. Mance, Double Jeopardy: Schizophrenia and Substance Use, Am J Drug Alcohol Abuse, vol.26, issue.3, pp.343-53, 2000.

N. D. Volkow, Substance Use Disorders in Schizophrenia-Clinical Implications of Comorbidity, vol.35, pp.469-72, 2009.

J. P. Swazey, Chlorpromazine in psychiatry; a study of therapeutic innovation, 1974.

C. L. Zirkle, To tranquilizers and antidepressants: from antimalarials and antihistamines, How Modern Medicines Are Discovered, pp.55-77, 1973.

W. W. Shen, A history of antipsychotic drug development. Compr Psychiatry, vol.40, pp.407-421, 1999.

H. Gilman, P. R. Van-ess, and D. A. Shirley, The metalation of 10-phenylphenothiazine and of 10-ethyl-phenothiazine, J Am Chem Soc, vol.66, pp.1214-1216, 1944.

S. Courvoisier,

L. 'encéphale, , vol.45, pp.1248-57, 1956.

S. Courvoisier, J. Fournel, R. Ducrot, M. Kolsky, and P. Koetschet, Pharmacodynamic properties of 3-chloro-10-(3-dimethylaminopropyl)-phenothiazine hydrochloride (R.P. 4560); experimental study of a new substance used in potentialized anesthesia and in artificial hibernation, Arch Int Pharmacodyn Ther, vol.92, issue.3-4, pp.305-61, 1953.

H. Laborit, P. Huguenard, and R. Alluaume,

, Presse Med, vol.60, issue.10, pp.206-214, 1952.

P. Hamon and . Velluz,

, Ann Med Psychol, vol.110, issue.1, pp.331-336, 1952.

J. Delay, P. Deniker, and J. M. Harl,

, Ann Med Psychol, vol.110, issue.2, pp.112-119, 1952.

, The PubChem Project, 2018.

J. Elkes and C. Elkes, Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic Patients, Br Med J, vol.2, issue.4887, pp.560-565, 1954.

F. J. Ayd, The early history of modern psychopharmacology, Neuropsychopharmacology, vol.5, pp.531-540, 1991.

A. Gaillard and M. Poirier,

, Soins Psychiatr, issue.286, pp.25-34, 2013.

P. A. Lambert, M. Beaujard, A. Achaintre, P. Broussolle, J. Perrin et al.,

, Ann Med Psychol, vol.115, issue.2, pp.291-297, 1957.

P. Divry, J. Bobon, J. Collard, A. Pinchard, and E. Nols, Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent

, Acta Neurol Psychiatr Belg, vol.59, issue.3, pp.337-66, 1959.

C. Massaut, J. Chantraine, E. Meurice, R. Pairoux, J. Paquay et al.,

, Acta Neurol Psychiatr Belg, vol.62, pp.651-61, 1962.

P. Borenstein, P. Cujo, C. Champion, and C. Olivenstein, Study of a new psychotropic agent: sulpiride (1403 RD). II. Clinical and electroencephalographic study

, Ann Med Psychol, vol.2, issue.1, pp.100-108, 1968.

M. P. Bishop and D. M. Gallant, Loxapine: a controlled evaluation in chronic schizophrenic patients, Curr Ther Res Clin Exp, vol.12, issue.9, pp.594-601, 1970.

. Pubchem and . Reserpine, , 2018.

J. Delay and P. Deniker, 38 cas de psychoses traitées par la cure prolongée et continue de 4560RP. Comptes rendus du 50 congrès des médecins aliénistes et neurologistes de Langue Française, pp.503-516, 1952.

J. Delay and P. Deniker, Methodes chimiotherapiques en psychiatrie: les nouveaux medicaments psychotropes, 1961.

C. King and L. Voruganti, What's in a name? The evolution of the nomenclature of antipsychotic drugs, J Psychiatry Neurosci, vol.27, issue.3, pp.168-75, 2002.

H. Terzian, Study of the action of largactil and pendiomide on the electrical activity of the rabbit brain, Rev Neurol, vol.91, pp.445-53, 1954.

H. Terzian,

, Sem Hopitaux Organe Fonde Par Assoc Enseign Med Hopitaux Paris, vol.30, pp.838-879, 1954.

C. Berthier and M. Bonneru-couchoud, Problème d'intégration psycho-biologique soulevés par l'utilisation de la chlorpromazine en particulier

N. Spécial, , pp.632-644, 1956.

N. W. Winkelman, Chlorpromazine in the treatment of neuropsychiatric disorders, J Am Med Assoc, vol.155, issue.1, pp.18-21, 1954.

A. Carlsson and M. Lindqvist, Effect of Chlorpromazine Or Haloperidol On Formation Of 3methoxytyramine And Normetanephrine In Mouse Brain, Acta Pharmacol Toxicol (Copenh), vol.20, pp.140-144, 1963.

Y. Landry and J. Gies, Pharmacologie : des cibles vers l'indication thérapeutique : cours et exercices corrigés, 2009.

H. Solomon, . Snyder, P. Shailesh, H. I. Banerjee, D. Yamamura et al., Drugs, Neurotransmitters, and Schizophrenia | Science, vol.21, pp.1243-1253, 1974.

J. Michael, N. S. Kuhar, and . Pilotte, Neurochemical changes in cocaine withdrawal, Trends in Pharmacological Sciences, vol.17, issue.7, pp.260-264, 1996.

E. J. Nestler, S. E. Hyman, and R. C. Malenka, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Higher Cognitive Function and Behavioral Control, p.318, 2018.

F. J. Ayd, A survey of drug-induced extrapyramidal reactions, JAMA, vol.175, pp.1054-60, 1961.

J. Sigwald, D. Bouttier, C. Raymond, and P. Pichot, Quatre cas de dyskinésie, facio-buccolinguo-masticatrice à l'évolution prolongée secondaire à un traitement par les neuroleptiques, Rev Neurol, vol.100, pp.751-755, 1959.

I. Besnard, V. Auclair, G. Callery, C. Gabriel-bordenave, and C. Roberge, Antipsychoticdrug-induced hyperprolactinemia: Physiopathology, clinical features and guidance

L. Farde, A. Nordström, F. Wiesel, S. Pauli, C. Halldin et al., Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects. Arch Gen Psychiatry, vol.49, pp.538-582, 1992.

N. Ginovart and S. Kapur, Role of Dopamine D2 Receptors for Antipsychotic Activity, Handb Exp Pharmacol, vol.212, pp.27-52, 2012.

, Meta regression: Relationship between antipsychotic receptor binding profiles and sideeffects, Prog Neuropsychopharmacol Biol Psychiatry, vol.84, pp.272-81, 2018.

H. Hippius, The founding of the CINP and the discovery of clozapine, The Psychopharmacologists, pp.185-213, 1996.

H. Gross and E. Langner, Das Wirkungprofil eines chemischen neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe, Wien Med Wochenschr, vol.116, pp.814-816, 1966.

D. Bente, M. Engelmeier, K. Heinrich, W. Schmitt, and H. Hippius, Klinische Untersungen mit einem neuroleptisch wirksamen Dibenzothiazepin-Derivat, Arzneimittelforschung, vol.16, pp.314-316, 1966.

J. Angst, U. Jaenicke, A. Padrutt, and C. Scharfetter, Ergebnisseeines Doppelblindversuches von HF 1854 (8-Chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b, e) (1,4)diazepin) im Vergleich zu Levomepromazin, Pharrnackopsychiatrie, vol.4, pp.192-200, 1971.

H. J. Haase, Extrapyramidal modification of fine movements: a 'conditio sine qua non' of the fundamental therapeutic action of neuroleptic drugs, Rev Can Biol, vol.20, pp.425-474, 1961.

J. Idänpään-heikkilä, E. Alhava, M. Olkinuora, and I. P. Palva, Agranulocytosis during treatment with chlozapine, Eur J Clin Pharmacol, vol.11, issue.3, pp.193-201, 1977.

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, vol.45, pp.789-96, 1988.

L. Justin-besançon, M. Thominet, C. Laville, and J. Margarit,

, Comptes Rendus Hebd Seances Acad Sci Ser Sci Nat, vol.265, issue.17, pp.1253-1257, 1967.

M. Bohbot, L. Doare, and B. Diquet, Determination of a new benzamide, amisulpride, in human plasma by reversed-phase ion-pair high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.416, pp.414-419, 1987.

P. A. Janssen, C. J. Niemegeers, F. Awouters, K. H. Schellekens, A. A. Megens et al., Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties, J Pharmacol Exp Ther, vol.244, issue.2, pp.685-93, 1988.

N. A. Keks and C. Culhane, Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs, vol.8, pp.443-52, 1999.

B. Fulton, K. Goa, and . Olanzapine, A Review of its Pharmacological Properties and Therapeutic Efficacy in the Management of Schizophrenia and Related Psychoses, vol.53, 1997.

N. H. Jensen, R. M. Rodriguiz, M. G. Caron, W. C. Wetsel, R. B. Rothman et al., Ndesalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity, vol.33, pp.2303-2315, 2008.

K. Bui, W. Earley, and S. Nyberg, Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications, Curr Med Res Opin, vol.29, issue.7, pp.813-838, 2013.

T. Swainston-harrison and C. M. Perry, Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder, Drugs, vol.64, issue.15, pp.1715-1751, 2004.

S. Kasper, Do we need another atypical antipsychotic? Eur Neuropsychopharmacol, vol.18, pp.146-52, 2008.

N. Moore, Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed, Int J Psychiatry Clin Pract, vol.6, issue.1, pp.3-9, 2002.

M. Shahid, G. B. Walker, S. H. Zorn, and E. Wong, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature, J Psychopharmacol Oxf Engl, vol.23, issue.1, pp.65-73, 2009.

A. M. Matar, M. Abdel-mawgoud, and S. Skov, Zuclopenthixol: a new generation of antipsychotic drugs. An open clinical trial, J Clin Psychopharmacol, vol.10, issue.4, pp.283-289, 1990.

R. Rxulti and . Chmp, , 2018.

F. Montastruc, A. Palmaro, H. Bagheri, L. Schmitt, J. Montastruc et al., Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase, Eur Neuropsychopharmacol, vol.25, issue.10, pp.1556-65, 2015.

G. J. Macdonald and J. M. Bartolomé, A decade of progress in the discovery and development of 'atypical' antipsychotics, Prog Med Chem, vol.49, pp.37-80, 2010.

B. J. Kinon and J. A. Lieberman, Mechanisms of action of atypical antipsychotic drugs: a critical analysis, Psychopharmacology (Berl), vol.124, issue.1-2, pp.2-34, 1996.

G. Remington and S. Kapur, Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl), vol.148, pp.3-15, 2000.

H. Y. Meltzer, S. Matsubara, and J. C. Lee, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values, J Pharmacol Exp Ther, vol.251, issue.1, pp.238-284, 1989.

J. Gerlach and L. Peacock, New antipsychotics: the present status, Int Clin Psychopharmacol, vol.10, issue.3, pp.39-48, 1995.

J. L. Waddington and E. O'callaghan, What Makes an Antipsychotic 'Atypical'? CNS Drugs, vol.7, pp.341-347, 1997.

S. Kapur, R. B. Zipursky, and R. G. , Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia, Am J Psychiatry, vol.156, issue.2, pp.286-93, 1999.

C. Owens and D. , Antipsychotics: is it time to end the generation game? Prescriber, 2011.

P. Seeman, M. Chau-wong, J. Tedesco, and K. Wong, Brain receptors for antipsychotic drugs and dopamine: direct binding assays, Proc Natl Acad Sci U S A, vol.72, issue.11, pp.4376-80, 1975.

D. M. Weiner, E. S. Burstein, N. Nash, G. E. Croston, E. A. Currier et al., Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics, vol.299, pp.268-76, 2001.

P. Seeman, H. C. Guan, V. Tol, and H. H. , Dopamine D4 receptors elevated in schizophrenia, Nature, vol.365, issue.6445, pp.441-446, 1993.

P. Seeman, Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.7, pp.261-84, 1992.

P. Seeman, T. Lee, M. Chau-wong, and K. Wong, Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature, vol.261, issue.5562, pp.717-726, 1976.

S. R. George, M. Watanabe, D. Paolo, T. Falardeau, P. Labrie et al., The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form, Endocrinology, vol.117, issue.2, pp.690-697, 1985.

S. Nyberg, A. L. Nordström, C. Halldin, and L. Farde, Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man, Int Clin Psychopharmacol, vol.10, issue.3, pp.81-86, 1995.

B. Küfferle, J. Tauscher, S. Asenbaum, C. Vesely, I. Podreka et al., IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol, Psychopharmacology (Berl), vol.133, issue.4, pp.323-331, 1997.

P. Seeman, Atypical antipsychotics: mechanism of action, Can J Psychiatry Rev Can Psychiatr, vol.47, issue.1, pp.27-38, 2002.

S. Kapur and P. Seeman, Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis, Am J Psychiatry

, , 2018.

G. Chouinard, L. Kopala, A. Labelle, L. Beauclair, S. V. Johnson et al., Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group, Can J Psychiatry Rev Can Psychiatr, vol.43, issue.10, pp.1018-1043, 1998.

K. Sahlholm, D. Marcellino, J. Nilsson, S. O. Ögren, K. Fuxe et al., Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor, Int J Neuropsychopharmacol, vol.17, issue.1, pp.149-55, 2014.

I. Kusumi, S. Boku, Y. Takahashi, K. T. Brady, and J. M. Roberts, Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis, Psychiatry Clin Neurosci, vol.69, issue.5, pp.344-52, 1995.

D. I. Lubman and M. Berk, Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: where is the evidence? Acta Neuropsychiatr, vol.22, pp.95-102, 2010.

L. Dixon, G. Haas, P. Weiden, J. Sweeney, and A. Frances, Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports, Schizophr Bull, vol.16, issue.1, pp.69-79, 1990.

J. Smith and S. Hucker, Schizophrenia and substance abuse, Br J Psychiatry J Ment Sci, vol.165, issue.1, pp.13-21, 1994.

P. A. Broderick, D. N. Rahni, and Y. Zhou, Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior, Prog Neuropsychopharmacol Biol Psychiatry, vol.27, issue.6, pp.1037-54, 2003.

W. C. Drevets, C. Gautier, J. C. Price, D. J. Kupfer, P. E. Kinahan et al., Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria, Biol Psychiatry, vol.49, issue.2, pp.81-96, 2001.

D. A. Smelson, A. Roy, and M. Roy, Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients, Can J Psychiatry Rev Can Psychiatr, vol.42, issue.9, p.984, 1997.

N. D. Volkow, G. J. Wang, J. S. Fowler, J. Logan, S. J. Gatley et al., Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects, Nature, vol.386, issue.6627, pp.830-833, 1997.

N. D. Volkow, G. Wang, F. Telang, J. S. Fowler, J. Logan et al., Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement, J Neurosci Off J Soc Neurosci, vol.27, issue.46, pp.12700-12706, 2007.

S. G. Siris, Pharmacological treatment of substance-abusing schizophrenic patients, Schizophr Bull, vol.16, issue.1, pp.111-133, 1990.

J. Hellewell, Treatment-resistant schizophrenia: Reviewing the options and identifying the way forward, vol.60

H. Y. Meltzer, Clozapine: balancing safety with superior antipsychotic efficacy, Clin Schizophr Relat Psychoses, vol.6, issue.3, pp.134-178, 2012.

H. Y. Meltzer, Treatment-resistant schizophrenia-the role of clozapine, Curr Med Res Opin, vol.14, issue.1, pp.1-20, 1997.

J. Tiihonen, J. Lönnqvist, K. Wahlbeck, T. Klaukka, L. Niskanen et al., 11year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), Lancet Lond Engl, vol.374, issue.9690, pp.620-627, 2009.

H. Y. Meltzer and G. Okayli, Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment, Am J Psychiatry, vol.152, issue.2, pp.183-90, 1995.

G. Parkinson-study, Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease, N Engl J Med, vol.340, issue.10, pp.757-63, 199911.

T. M. Kelly, D. C. Daley, and A. B. Douaihy, Treatment of substance abusing patients with comorbid psychiatric disorders, Addict Behav, vol.37, issue.1, pp.11-24, 2012.

J. A. Lieberman, T. S. Stroup, J. P. Mcevoy, M. S. Swartz, R. A. Rosenheck et al., Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, vol.353, issue.12, pp.1209-1232, 2005.

P. B. Jones, T. Barnes, L. Davies, G. Dunn, H. Lloyd et al., Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1), vol.63, pp.1079-87, 2006.

D. Naber and M. Lambert, The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians, CNS Drugs, vol.23, issue.8, pp.649-59, 2009.

J. Gerlach, New antipsychotics: classification, efficacy, and adverse effects, Schizophr Bull, vol.17, issue.2, pp.289-309, 1991.

G. S. Robertson, H. Matsumura, and H. C. Fibiger, Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity, J Pharmacol Exp Ther, vol.271, issue.2, pp.1058-66, 1994.

H. Y. Meltzer, Update on typical and atypical antipsychotic drugs, Annu Rev Med, vol.64, pp.393-406, 2013.

J. M. Davis, N. Chen, and I. D. Glick, A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, vol.60, pp.553-64, 2003.

J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis, BMJ, vol.321, issue.7273, pp.1371-1377, 2000.

H. C. Kales, H. M. Kim, K. Zivin, M. Valenstein, L. S. Seyfried et al., Risk of mortality among individual antipsychotics in patients with dementia, Am J Psychiatry, vol.169, issue.1, pp.71-80, 2012.

R. M. Bilder, R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman et al., Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder, Am J Psychiatry, vol.159, issue.6, pp.1018-1046, 2002.

S. Yamin and K. Vaddadi, Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine, International Review of Psychiatry, vol.22, pp.2010-2012

R. Ganguly, J. A. Kotzan, L. S. Miller, K. K. , and M. B. Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, vol.65, pp.1377-88, 1998.

M. B. Bowers, C. M. Mazure, J. C. Nelson, and P. I. Jatlow, Psychotogenic drug use and neuroleptic response, Schizophr Bull, vol.16, issue.1, pp.81-86, 1990.

M. Soyka, C. Aichmüller, U. Bardeleben, M. Beneke, T. Glaser et al., Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study, Eur Addict Res, vol.9, issue.2, pp.65-72, 2003.

S. Potvin, T. Pampoulova, A. Mancini-marië, O. Lipp, R. Bouchard et al., Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder, J Neurol Neurosurg Psychiatry, vol.77, issue.6, pp.796-804, 2006.

P. Buckley, P. Thompson, L. Way, and H. Y. Meltzer, Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy, Am J Psychiatry, vol.151, issue.3, pp.385-394, 1994.

S. V. Zimmet, R. D. Strous, E. S. Burgess, S. Kohnstamm, and A. I. Green, Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey, J Clin Psychopharmacol, vol.20, issue.1, pp.94-102, 2000.

D. L. Kelly, E. A. Gale, and R. R. Conley, Clozapine treatment in patients with prior substance abuse. Can J Psychiatry Rev Can Psychiatr, vol.48, pp.111-115, 2003.

A. L. Bahorik, C. G. Greeno, G. Cochran, J. R. Cornelius, and S. M. Eack, Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia, Psychiatry Res, vol.253, pp.391-398, 2017.

D. A. Smelson, M. F. Losonczy, C. W. Davis, M. Kaune, J. Williams et al., Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence, Can J Psychiatry Rev Can Psychiatr, vol.47, issue.7, pp.671-676, 2002.

M. Casas, M. Gutiérrez, J. Gibert, J. Bobes, C. Roncero et al.,

, Actas Esp Psiquiatr, vol.29, issue.6, pp.380-385, 2001.

K. M. Kampman, H. Pettinati, K. G. Lynch, T. Sparkman, O. Brien et al., A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend, Jun, vol.5, issue.3, pp.265-73, 2003.

K. H. Littrell, R. G. Petty, N. M. Hilligoss, C. D. Peabody, and C. G. Johnson, Olanzapine treatment for patients with schizophrenia and substance abuse, J Subst Abuse Treat, vol.21, issue.4, pp.217-238, 2001.

D. A. Smelson, D. Ziedonis, J. Williams, M. F. Losonczy, J. Williams et al., The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report, J Clin Psychopharmacol, vol.26, issue.1, pp.9-12, 2006.

S. Potvin, E. Stip, and J. Y. Roy, The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency, Can J Psychiatry, vol.49, issue.10, p.711, 2004.

T. P. Beresford, L. Clapp, B. Martin, J. L. Wiberg, J. Alfers et al., Aripiprazole in schizophrenia with cocaine dependence: a pilot study, J Clin Psychopharmacol, vol.25, issue.4, pp.363-369, 2005.

B. Croissant, O. Klein, L. Gehrlein, A. Kniest, D. Hermann et al., Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series, Eur Psychiatry J Assoc Eur Psychiatr, vol.21, issue.8, pp.570-573, 2006.

A. Kennedy, A. E. Wood, A. J. Saxon, C. Malte, M. Harvey et al., Quetiapine for the treatment of cocaine dependence: an open-label trial, J Clin Psychopharmacol, vol.28, issue.2, pp.221-225, 2008.

H. B. Pinkofsky, A. M. Hahn, F. A. Campbell, J. Rueda, D. C. Daley et al., Reduction of opioid-withdrawal symptoms with quetiapine, J Clin Psychiatry, vol.66, issue.10, pp.1285-1293, 2005.

S. P. Sattar, S. C. Bhatia, and F. Petty, Potential benefits of quetiapine in the treatment of substance dependence disorders, J Psychiatry Neurosci JPN, vol.29, issue.6, pp.452-459, 2004.

E. B. Stuyt, T. A. Sajbel, and M. H. Allen, Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders, Am J Addict, vol.15, issue.2, pp.166-73, 2006.

S. L. Sayers, E. C. Campbell, J. Kondrich, S. C. Mann, J. Cornish et al., Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol, J Nerv Ment Dis, vol.193, issue.6, pp.379-86, 2005.

E. Akerele and F. R. Levin, Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia, Am J Addict, vol.16, issue.4, pp.260-268, 2007.

H. S. Temmingh, T. Williams, N. Siegfried, and D. J. Stein, Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. Cochrane Database Syst Rev, vol.1, p.11057, 2018.

T. P. Gilmer, C. R. Dolder, J. P. Lacro, D. P. Folsom, L. Lindamer et al., Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia, Am J Psychiatry, vol.161, issue.4, pp.692-701, 2004.

D. I. Velligan, M. Wang, P. Diamond, D. C. Glahn, D. Castillo et al., Relationships among subjective and objective measures of adherence to oral antipsychotic medications, Psychiatr Serv Wash DC, vol.58, issue.9, pp.1187-92, 2007.

M. M. Koola, H. J. Wehring, and D. L. Kelly, The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use, J Dual Diagn, vol.8, issue.1, pp.50-61, 2012.

D. I. Lubman, J. A. King, and D. J. Castle, Treating comorbid substance use disorders in schizophrenia, Int Rev Psychiatry Abingdon Engl, vol.22, issue.2, pp.191-201, 2010.

J. E. Olijslagers, T. R. Werkman, A. C. Mccreary, C. G. Kruse, and W. J. Wadman, Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action, Curr Neuropharmacol, vol.4, issue.1, pp.59-68, 2006.

S. Leucht, A. Cipriani, L. Spineli, D. Mavridis, D. Orey et al., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis, Lancet Lond Engl, vol.382, issue.9896, pp.951-62, 2013.

H. C. Margolese, G. Chouinard, T. T. Kolivakis, L. Beauclair, R. Miller et al., Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia, Can J Psychiatry Rev Can Psychiatr, vol.50, issue.11, pp.703-717, 2005.

C. U. Correll, S. Leucht, and J. M. Kane, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies, Am J Psychiatry, vol.161, issue.3, pp.414-439, 2004.

S. Chong, J. Tay, M. Subramaniam, E. Pek, and D. Machin, Mortality rates among patients with schizophrenia and tardive dyskinesia, J Clin Psychopharmacol, vol.29, issue.1, pp.5-8, 2009.

K. I. Melkersson, A. L. Hulting, and K. E. Brismar, Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses, J Clin Psychiatry, vol.61, issue.10, pp.742-751, 2000.

M. Ryan and J. H. Thakore, Physical consequences of schizophrenia and its treatment: the metabolic syndrome, Life Sci, vol.71, issue.3, pp.239-57, 2002.

J. W. Newcomer, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, vol.19, pp.1-93, 2005.

F. Gianfrancesco, A. Grogg, R. Mahmoud, and H. Nasrallah, Association of new-onset diabetes and antipsychotics: Findings from a large health plan database, Eur Neuropsychopharmacol-EUR NEUROPSYCHOPHARMACOL, vol.11, 2001.

D. R. Wilson, D. Souza, L. Sarkar, N. Newton, M. Hammond et al., New-onset diabetes and ketoacidosis with atypical antipsychotics, Schizophr Res, vol.59, issue.1, pp.1-6, 2003.

Y. Zhang, Y. Liu, Y. Su, Y. You, Y. Ma et al., The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry, vol.17, p.373, 2017.

G. P. Reynolds and S. L. Kirk, Metabolic side effects of antipsychotic drug treatmentpharmacological mechanisms, Pharmacol Ther, vol.125, issue.1, pp.169-79, 2010.

M. Malik and A. J. Camm, Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling, Drug Saf, vol.24, issue.5, pp.323-51, 2001.

P. S. Chohan, R. Mittal, and A. Javed, Antipsychotic Medication and QT Prolongation, Pak J Med Sci, vol.31, issue.5, pp.1269-71, 2015.

H. G. Kelly, J. E. Fay, and S. G. Laverty, Thioridazine Hydrochloride (Mellaril): Its Effect On The Electrocardiogram And A Report Of Two Fatalities With Electrocardiographic Abnormalities, Can Med Assoc J, vol.89, pp.546-54, 1963.

E. P. Harrigan, J. J. Miceli, R. Anziano, E. Watsky, K. R. Reeves et al., A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition, J Clin Psychopharmacol, vol.24, issue.1, pp.62-71, 2004.

C. U. Correll, From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics, Eur Psychiatry J Assoc Eur Psychiatr, vol.25, issue.2, pp.12-21, 2010.

S. R. Beach, C. M. Celano, P. A. Noseworthy, J. L. Januzzi, and J. C. Huffman, QTc prolongation, torsades de pointes, and psychotropic medications, Psychosomatics, vol.54, issue.1, pp.1-13, 2013.

S. H. Thomas, Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP), Acta Psychiatr Scand, vol.122, issue.5, pp.345-55, 2010.

E. Poluzzi, E. Raschi, U. Moretti, D. Ponti, and F. , Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS), Pharmacoepidemiol Drug Saf, vol.18, issue.6, pp.512-520, 2009.

T. Kishi, S. Matsunaga, and N. Iwata, Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials, Schizophr Bull, vol.42, issue.6, pp.1438-1483, 2016.

P. Fusar-poli, M. J. Kempton, and R. A. Rosenheck, Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials, Int Clin Psychopharmacol, vol.28, issue.2, pp.57-66, 2013.

F. Misawa, T. Kishimoto, K. Hagi, J. M. Kane, and C. U. Correll, Safety and tolerability of longacting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics, Schizophr Res, vol.176, issue.2-3, pp.220-250, 2016.

D. P. Mcdonnell, H. C. Detke, R. F. Bergstrom, P. Kothare, J. Johnson et al., Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism, BMC Psychiatry, vol.10, p.45, 2010.

H. C. Detke, D. P. Mcdonnell, E. Brunner, F. Zhao, S. Sorsaburu et al., Postinjection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases, BMC Psychiatry, vol.10, p.43, 2010.

L. Alphs, S. Gopal, K. Karcher, J. Kent, J. K. Sliwa et al., Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases, Curr Drug Saf, vol.6, issue.1, pp.43-48, 2011.

V. Novakovic, T. Adel, E. Peselow, and J. Lindenmayer, Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS), Clin Neuropharmacol, vol.36, issue.2, pp.59-62, 2013.

J. Delay and P. Deniker, Handbook of Clinical Neurology | The Human Hypothalamus: : Drug-induced extrapyramidal syndromes, Volum 6, pp.248-266, 1968.

V. R. Velamoor, Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf, vol.19, pp.73-82, 1998.

R. Velamoor, Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management, Asian J Psychiatry, vol.29, pp.106-115, 2017.

C. E. Corallo and D. Ernest, Atypical neuroleptic malignant syndrome with long-term clozapine. Crit Care Resusc J Australas Acad Crit Care Med, vol.9, pp.338-378, 2007.

S. N. Caroff, S. C. Mann, and E. C. Campbell, Atypical Antipsychotics and Neuroleptic Malignant Syndrome, Psychiatr Ann, vol.30, issue.5, pp.314-335, 2000.

G. Honigfeld, F. Arellano, J. Sethi, A. Bianchini, and J. Schein, Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry, J Clin Psychiatry, vol.59, pp.3-7, 1998.

P. Schulte, Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring, Ann Pharmacother, vol.40, issue.4, pp.683-691, 2006.

D. B. Merrill, G. W. Dec, and D. C. Goff, Adverse cardiac effects associated with clozapine, J Clin Psychopharmacol, vol.25, issue.1, pp.32-41, 2005.

S. J. Haas, R. Hill, H. Krum, D. Liew, A. Tonkin et al., Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during, Drug Saf, vol.30, issue.1, pp.47-57, 1993.

K. J. Ronaldson, P. B. Fitzgerald, A. J. Taylor, D. J. Topliss, and J. J. Mcneil, A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls, Aust N Z J Psychiatry, vol.45, issue.6, pp.458-65, 2011.

K. J. Ronaldson, P. B. Fitzgerald, and J. J. Mcneil, Clozapine-induced myocarditis, a widely overlooked adverse reaction, Acta Psychiatr Scand, vol.132, issue.4, pp.231-271, 2015.

, Aripiprazole par voie orale (ABILIFY® et génériques) : rappel des indications et des précautions d'emploi liées au risque de suicide-Lettre aux professionnels de santéANSM : Agence nationale de sécurité du médicament et des produits de santé, 2018.

M. Ulcickas-yood, G. Delorenze, C. P. Quesenberry, A. Tsai, S. Phillips et al., Epidemiologic study of aripiprazole use and the incidence of suicide events, Pharmacoepidemiol Drug Saf, vol.19, issue.11, pp.1124-1154, 2010.

V. Pinzani, Atypical antipsychotic misuse and adverse events: a review of the French Pharmacovigilance Database, 2018.

L. J. Kalverdijk, A multi-national comparison of antipsychotic drug use in children and adolescents, vol.11, p.55, 2005.

M. W. Shannon, S. W. Borron, and M. Burns, Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 1584.

M. A. Ciranni, T. E. Kearney, and K. R. Olson, Comparing acute toxicity of first-and secondgeneration antipsychotic drugs: a 10-year, retrospective cohort study, J Clin Psychiatry, vol.70, issue.1, pp.122-131, 2009.

B. M. Waters and K. G. Joshi, Intravenous quetiapine-cocaine use ('Q-ball'), Am J Psychiatry, vol.164, issue.1, pp.173-177, 2007.

R. M. Malow, J. A. West, S. A. Corrigan, J. M. Pena, and W. C. Lott, Cocaine and speedball users: differences in psychopathology, J Subst Abuse Treat, vol.9, issue.4, pp.287-91, 1992.

C. Chen, I. Shiah, W. Lee, S. Kuo, C. Huang et al., Dependence on quetiapine in combination with zolpidem and clonazepam in bipolar depression, Psychiatry Clin Neurosci, vol.63, issue.3, pp.427-435, 2009.

A. Terán, S. Majadas, and J. Galan, Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study, Subst Use Misuse, vol.43, issue.14, pp.2169-71, 2008.

D. Murphy, K. Bailey, M. Stone, and W. C. Wirshing, Addictive potential of quetiapine, Am J Psychiatry, vol.165, issue.7, p.918, 2008.

G. Tarasoff and K. Osti, Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada, Am J Psychiatry, vol.164, issue.2, p.350, 2007.

R. Dhar, A. Sidana, T. Singh, and . Olanzapine-dependence, Ger J Psychiatry, vol.13, 2010.

C. Lai, Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression, Prog Neuropsychopharmacol Biol Psychiatry, vol.34, issue.7, pp.1363-1367, 2010.

N. A. Kumsar and A. Erol, Olanzapine abuse, Subst Abus, vol.34, issue.1, pp.73-77, 2013.

T. Paparrigopoulos, D. Karaiskos, and J. Liappas, Quetiapine: another drug with potential for misuse? A case report, J Clin Psychiatry, vol.69, issue.1, pp.162-165, 2008.

J. M. Pierre, High-dose quetiapine in treatment refractory schizophrenia, Schizophr Res, vol.73, issue.2-3, pp.373-378, 2005.

G. P. Pullen, N. R. Best, and J. Maguire, Anticholinergic drug abuse: a common problem, Br Med J (Clin Res Ed, vol.289, issue.6445, pp.612-615, 1984.

B. A. Fischer and D. L. Boggs, The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature, Neurosci Biobehav Rev, vol.34, issue.4, pp.555-563, 2010.

A. G. Halpert, M. C. Olmstead, and R. J. Beninger, Mechanisms and abuse liability of the antihistamine dimenhydrinate, Neurosci Biobehav Rev, vol.26, issue.1, pp.61-68, 2002.

W. K. Kroeze, S. J. Hufeisen, B. A. Popadak, S. M. Renock, S. Steinberg et al., H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.28, issue.3, pp.519-545, 2003.

S. Kapur and P. Seeman, Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action, J Psychiatry Neurosci JPN, vol.25, pp.161-167, 2000.

U. Wagner, P. Segura-torres, T. Weiler, and J. P. Huston, The tuberomammillary nucleus region as a reinforcement inhibiting substrate: facilitation of ipsihypothalamic selfstimulation by unilateral ibotenic acid lesions, Brain Res, vol.613, issue.2, pp.269-74, 1993.

A. Sannerud, C. Kaminski, B. Griffiths, and R. , Maintenance of H1 Antagonists Self-Injection in Baboons, Exp Clin Psychopharmacol, vol.3, pp.26-32, 1995.

B. T. Chen, F. W. Hopf, and A. Bonci, Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse, Ann N Y Acad Sci, vol.1187, pp.129-168, 2010.

R. A. Chambers, J. H. Krystal, and D. W. Self, A neurobiological basis for substance abuse comorbidity in schizophrenia, Biol Psychiatry, vol.50, issue.2, pp.71-83, 2001.

F. Tascedda, J. M. Blom, N. Brunello, K. Zolin, M. Gennarelli et al., Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats, Biol Psychiatry, vol.50, issue.2, pp.117-139, 2001.

B. Abler, S. Erk, and H. Walter, Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebocontrolled fMRI study. Psychopharmacology (Berl), vol.191, pp.823-856, 2007.

O. V. Tcheremissine, Is quetiapine a drug of abuse? Reexamining the issue of addiction, Expert Opin Drug Saf, vol.7, issue.6, pp.739-787, 2008.

H. J. Cha, H. Lee, J. Ahn, J. Kim, E. J. Jeong et al., Dependence potential of quetiapine: behavioral pharmacology in rodents, Biomol Ther, vol.21, issue.4, pp.307-319, 2013.

A. E. Mclelland, M. T. Martin-iverson, and R. J. Beninger, The effect of quetiapine (Seroquel TM ) on conditioned place preference and elevated plus maze tests in rats when administered alone and in combination with (+)-amphetamine. Psychopharmacology (Berl), vol.231, pp.4349-59, 2014.

R. E. Brutcher, S. H. Nader, and M. A. Nader, Evaluation of the Reinforcing Effect of Quetiapine, Alone and in Combination with Cocaine, in Rhesus Monkeys, J Pharmacol Exp Ther, vol.356, issue.2, pp.244-50, 2016.

V. C. Campbell, T. A. Kopajtic, A. H. Newman, and J. L. Katz, Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs, J Pharmacol Exp Ther, vol.315, issue.2, pp.631-671, 2005.

M. L. Banks, M. L. Andersen, K. S. Murnane, R. C. Meyer, and L. L. Howell, Behavioral and neurochemical effects of cocaine and diphenhydramine combinations in rhesus monkeys, Psychopharmacology (Berl), vol.205, issue.3, pp.467-74, 2009.

M. E. Mclarnon, H. G. Fulton, C. Macisaac, and S. P. Barrett, Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program, J Clin Psychopharmacol, vol.32, issue.5, pp.721-724, 2012.

D. L. Rowe, Off-label prescription of quetiapine in psychiatric disorders, Expert Rev Neurother, vol.7, issue.7, pp.841-52, 2007.

O. Karamustafal?o?lu, A. Reif, M. Atmaca, D. Gonzalez, M. Moreno-manzanaro et al., Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME). BMC Psychiatry, vol.14, p.246, 2014.

L. Reccoppa, Less abuse potential with XR formulation of quetiapine?, Am J Addict, vol.20, issue.2, p.178, 2011.

M. George, M. Haasz, A. Coronado, S. Salhanick, L. Korbel et al., Acute dyskinesia, myoclonus, and akathisa in an adolescent male abusing quetiapine via nasal insufflation: a case study, BMC Pediatr, vol.13, p.187, 2013.

A. Srivastava, V. Patil, D. Silva-pereira, and Y. , A case series of quetiapine addiction/dependence, Ger J Psychiatry, vol.16, pp.152-157, 2013.

C. Heilbronn, B. Lloyd, P. Mcelwee, A. Eade, and D. I. Lubman, Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances, Drug Alcohol Rev, vol.32, issue.4, pp.405-416, 2013.

A. Sarker, K. O'connor, R. Ginn, M. Scotch, K. Smith et al., Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter, Drug Saf, vol.39, issue.3, pp.231-271, 2016.

S. Says and . Chiffres,

M. Blog-du, , 2018.

L. Wyte-oxycotton, , 2018.

, Lord Infamous (Ft. Lil Wyte, Partee & Project Pat)-Pill Popper, 2018.

J. B. Stafford and L. Burns, Australian drug trends 2011: findings from the illicit drug reporting system (idrs), 2012.

N. L. Keltner and D. E. Vance, Biological perspectives incarcerated care and quetiapine abuse, Perspect Psychiatr Care, vol.44, issue.3, pp.202-208, 2008.

N. Hunfeld, E. M. Westerman, D. J. Boswijk, .. M. De-haas-j-a, .. M. Van-putten et al., Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases, Ther Drug Monit, vol.28, issue.2, pp.185-194, 2006.

M. Bodmer, T. Burkard, O. Kummer, R. Beyrau, S. Krähenbühl et al., Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose, Ther Drug Monit, vol.30, issue.4, pp.553-559, 2008.

F. Eyer, R. Pfab, N. Felgenhauer, T. Strubel, B. Saugel et al., Clinical and analytical features of severe suicidal quetiapine overdoses-a retrospective cohort study, Clin Toxicol Phila Pa, vol.49, issue.9, pp.846-53, 2011.

V. Bédard and P. A. Dubé, Revue des particularités des intoxications aiguës à la quétiapine | Toxicologie clinique, Bulletin d'information toxicologique, vol.28, p.3, 2018.

W. Klein-schwartz, E. K. Schwartz, and B. D. Anderson, Evaluation of quetiapine abuse and misuse reported to poison centers, J Addict Med, vol.8, issue.3, pp.195-203, 2014.

, Annual Report of the American Association of Poison Control Centers ' National Poison Data System (NPDS): 28th Annual Report, 2018.

H. Peyrière, C. Diot, C. Eiden, and P. Petit, Réseau des Centres d'Addictovigilance

. Therapie, , 2015.

L. Hazell and S. Shakir, Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-96, 2006.

M. E. Mattson, V. A. Albright, J. Yoon, and C. L. Council, Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN), Subst Abuse Res Treat, vol.9, pp.39-46, 2015.

F. Schifano, Psychoactive drug or mystical incense? Overview of the online available information on Spice products, International Journal of Culture and Mental Health, vol.2, issue.2, 2018.

. Olanzapine-|-drugs-forum, , 2018.

O. O. Oluwabusi, L. Lobach, U. Akhtar, B. Youngman, and P. J. Ambrosini, Synthetic cannabinoid-induced psychosis: two adolescent cases, J Child Adolesc Psychopharmacol, vol.22, issue.5, pp.393-398, 2012.

T. Leelahanaj, R. Kongsakon, and P. Netrakom, A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis, J Med Assoc Thail Chotmaihet Thangphaet, vol.88, issue.3, pp.43-52, 2005.

C. Blanco, Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States, Drug and Alcohol Dependence, vol.90, pp.252-260, 1991.

W. Assist-working and . Group, The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility, Addict Abingdon Engl, vol.97, issue.9, pp.1183-94, 2002.

S. Darke, Pathways to heroin dependence: time to re-appraise self-medication, Addict Abingdon Engl, vol.108, issue.4, pp.659-67, 2013.

P. Manu, L. Dima, M. Shulman, D. Vancampfort, D. Hert et al., Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management, Acta Psychiatr Scand, vol.132, issue.2, pp.97-108, 2015.

F. J. Santolaria-fernández, J. L. Gómez-sirvent, C. E. González-reimers, J. Batista-lópez, J. et al., Nutritional assessment of drug addicts. Drug Alcohol Depend, vol.38, pp.11-19, 1995.

T. Malekshahi, N. Tioleco, N. Ahmed, A. Campbell, and D. Haller, Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse, J Subst Abuse Treat, vol.48, issue.1, pp.8-12, 2015.

L. Klein, S. Bangh, and J. B. Cole, Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics, West J Emerg Med, vol.18, issue.2, pp.243-50, 2017.

S. Kim, G. Lee, E. Kim, H. Jung, and J. Chang, Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior, J Res Pharm Pract, vol.6, issue.1, pp.12-17, 2017.

J. A. Inciardi, H. L. Surratt, S. P. Kurtz, and T. J. Cicero, Mechanisms of prescription drug diversion among drug-involved club-and street-based populations, Pain Med Malden Mass, vol.8, issue.2, pp.171-83, 2007.

J. M. Zito, D. J. Safer, S. Dosreis, J. F. Gardner, M. Boles et al., Trends in the prescribing of psychotropic medications to preschoolers, JAMA, vol.283, issue.8, pp.1025-1055, 2000.

H. Verdoux, M. Tournier, and B. Bégaud, Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies, Acta Psychiatr Scand, vol.121, issue.1, pp.4-10, 2010.

A. F. Lehman, J. A. Lieberman, L. B. Dixon, T. H. Mcglashan, A. L. Miller et al., Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry, vol.161, issue.2, pp.1-56, 2004.

, NICE MTA Guidance 43-Guidance on the use of newer (atypical) antipsychotic drugs for treatment of schizophrenia, 2018.

R. Weisler, R. S. Mcintyre, and M. Bauer, Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy, Expert Rev Neurother, vol.13, issue.11, pp.1183-200, 2013.

N. S. Philip, K. Mello, L. L. Carpenter, A. R. Tyrka, and L. H. Price, Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use, Ann Clin Psychiatry Off J Am Acad Clin Psychiatr, vol.20, issue.1, pp.15-20, 2008.

W. Thompson, T. Quay, C. Rojas-fernandez, B. Farrell, and L. M. Bjerre, Atypical antipsychotics for insomnia: a systematic review, Sleep Med, vol.22, pp.13-20, 2016.

J. Brett, Concerns about quetiapine. Aust Prescr, vol.38, pp.95-102, 2015.

A. Haridas, . Mrcpsych, D. Kushon, S. Gurmu, and O. Oluwabusi, Smoking Quetiapine: A "Maq Ball"? Prim Psychiatry, vol.17, pp.38-47, 2010.

G. S. Alexopoulos, J. Streim, D. Carpenter, and J. P. Docherty, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients, J Clin Psychiatry, vol.65, issue.2, pp.5-99, 2004.

D. James, P. , S. Fida, A. Konovalov, P. et al., Non-medical use of olanzapine by people on methadone treatment, vol.40, pp.314-321, 2016.

A. A. Grace, The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving, Addict Abingdon Engl, vol.95, issue.2, pp.119-128, 2000.

J. P. Bolam and T. J. Ellender, Histamine and the striatum, Neuropharmacology, vol.2016, pp.74-84
DOI : 10.1016/j.neuropharm.2015.08.013

URL : https://doi.org/10.1016/j.neuropharm.2015.08.013

G. F. Koob, Neural Mechanisms of Drug Reinforcement, Ann N Y Acad Sci, vol.654, issue.1, pp.171-91, 1992.

V. K. Patadia, P. Coloma, M. J. Schuemie, R. Herings, R. Gini et al., Using real-world healthcare data for pharmacovigilance signal detection-the experience of the EU-ADR project, Expert Rev Clin Pharmacol, vol.8, issue.1, pp.95-102, 2015.

A. Casati, R. Sedefov, and T. Pfeiffer-gerschel, Misuse of medicines in the European Union: a systematic review of the literature, Eur Addict Res, vol.18, issue.5, pp.228-273, 2012.

F. Jalali, R. Afshari, and A. Babaei, Smoking crushed hyoscine/scopolamine tablets as drug abuse. Subst Use Misuse, vol.49, pp.793-800, 2014.
DOI : 10.3109/10826084.2014.880178

L. Garcin, L. Roch, M. Agbessi, C. Lobut, J. Lecoeur et al., Arch Pediatr Organe Off Soc Francaise Pediatr, vol.23, pp.1165-1173, 2016.

K. B. Hoffman, A. R. Demakas, M. Dimbil, N. P. Tatonetti, and C. B. Erdman, Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS), Drug Saf, vol.37, issue.11, pp.971-80, 2014.

E. Jouanjus, V. Gibaja, J. Kahn, F. Haramburu, and A. Daveluy, Signal identification in addictovigilance: the functioning of the French system, Therapie, vol.70, issue.2, pp.113-144, 2015.

U. Story, , 2018.

, CIM-10 Version, 2008.

W. Index, , 2018.

. Umc-|-vigilyze, , 2018.

A. Bate, M. Lindquist, I. R. Edwards, S. Olsson, R. Orre et al., A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol, vol.54, issue.4, pp.315-336, 1998.

G. N. Norén, J. Hopstadius, and A. Bate, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery, Stat Methods Med Res, vol.22, issue.1, pp.57-69, 2013.

, Guideline on The Use Of Statistical Signal Detection Methods In The Eudravigilance Data Analysis System, 2018.

T. Renoir, Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved, Front Pharmacol, vol.4, p.45, 2013.

T. Bergvall, G. N. Norén, and M. Lindquist, vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues, Drug Saf, vol.37, issue.1, pp.65-77, 2014.
DOI : 10.1007/s40264-013-0131-x

B. Bégaud, K. Martin, F. Haramburu, and N. Moore, Rates of spontaneous reporting of adverse drug reactions in France, JAMA, vol.288, issue.13, p.1588, 2002.

A. Cerovecki, R. Musil, A. Klimke, F. Seemüller, E. Haen et al., Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations, CNS Drugs, vol.27, issue.7, pp.545-72, 2013.
DOI : 10.1007/s40263-013-0079-5

S. M. Stahl and D. K. Shayegan, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice, J Clin Psychiatry, vol.64, pp.6-12, 2003.

M. S. Gómez-criado, M. Bernardo, . Florez-t-de, J. R. Gutiérrez, R. Gandía et al., Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review, Pharmacotherapy, vol.25, issue.11, pp.1660-1665, 2005.

R. Maher and G. Theodore, Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics, Supplement to Journal of Managed Care Pharmacy, vol.18, issue.5, 2012.

M. Pompili, C. Verzura, G. Trovini, A. Buscajoni, G. Falcone et al., Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders, Expert Opin Drug Saf, vol.17, issue.2, pp.197-205, 2018.

G. P. Molnar, L. C. Grimsich, G. Catalano, and M. C. Catalano, Acute lurasidone overdose, J Clin Psychopharmacol, vol.34, issue.6, pp.768-70, 2014.
DOI : 10.1097/jcp.0000000000000224

G. I. Spielmans, M. I. Berman, E. Linardatos, N. Z. Rosenlicht, A. Perry et al., Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes, PLoS Med, vol.10, issue.3, p.1001403, 2013.

J. Faillie, Case-non case studies: Principles, methods, bias and interpretation
URL : https://hal.archives-ouvertes.fr/hal-01741153

. Therapie, , 2017.

A. K. Morin, Possible intranasal quetiapine misuse, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.64, issue.7, pp.723-728, 2007.
DOI : 10.2146/ajhp060226

J. Ballon and T. S. Stroup, Polypharmacy for schizophrenia, Curr Opin Psychiatry, vol.26, issue.2, pp.208-221, 2013.
DOI : 10.1097/yco.0b013e32835d9efb

URL : http://europepmc.org/articles/pmc4026924?pdf=render

C. Rummel-kluge, W. Kissling, and S. Leucht, Antidepressants for the negative symptoms of schizophrenia, Cochrane Database of Systematic Reviews, 2006.

J. Tiihonen, J. T. Suokas, J. M. Suvisaari, J. Haukka, and P. Korhonen, Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry, vol.69, pp.476-83, 2012.

P. Thoma and I. Daum, Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings, Psychiatry Clin Neurosci, vol.67, issue.6, pp.367-83, 2013.

C. Yuodelis-flores and R. K. Ries, Addiction and suicide: A review, Am J Addict, vol.24, issue.2, pp.98-104, 2015.
DOI : 10.1111/ajad.12185

. Umc-|-vigibase, , 2018.

M. H. Meier, A. Caspi, A. Reichenberg, R. Keefe, H. L. Fisher et al., Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study, Am J Psychiatry, vol.171, issue.1, pp.91-101, 2014.

G. Cottrell, M. Cot, and J. Mary, L'imputation multiple des données manquantes aléatoirement : concepts généraux et présentation d'une méthode Monte-Carlo. Rev DÉpidémiologie Santé Publique, vol.57, pp.361-72, 2009.
DOI : 10.1016/j.respe.2009.04.011

R. R. Reeves and J. C. Brister, Additional evidence of the abuse potential of quetiapine, South Med J, vol.100, issue.8, pp.834-840, 2007.

F. Montastruc, F. Salvo, M. Arnaud, B. Bégaud, and A. Pariente, Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®), Drug Saf, vol.39, issue.7, pp.689-96, 2016.

D. K. Wellisch, G. R. Gay, D. R. Wesson, and D. E. Smith, The Psychotic Heroin Addict, J Psychedelic Drugs, vol.4, issue.1, pp.46-55, 1971.

A. M. Kern, S. C. Akerman, and B. R. Nordstrom, Opiate dependence in schizophrenia: case presentation and literature review, J Dual Diagn, vol.10, issue.1, pp.52-59, 2014.

M. D. Sullivan, M. J. Edlund, L. Zhang, J. Unützer, and K. B. Wells, Association between mental health disorders, problem drug use, and regular prescription opioid use, Arch Intern Med, vol.166, pp.2087-93, 2006.

A. Gallini, S. Andrieu, J. M. Donohue, N. Oumouhou, M. Lapeyre-mestre et al., Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings, Eur Neuropsychopharmacol, vol.24, issue.1, pp.95-104, 2014.

S. Wilkinson and R. T. Mulder, Antipsychotic prescribing in New Zealand between, N Z Med J, vol.131, pp.61-68, 1480.

S. Ilyas and J. Moncrieff, Trends in prescriptions and costs of drugs for mental disorders in England, Br J Psychiatry J Ment Sci, issue.5, pp.393-401, 0200.

U. Uppsala, Guideline for using VigiBase data in studies, 2010.